Clinical trial of SGX-001 for the treatment of p47 Chronic Granulomatous Disease (CGD)
Latest Information Update: 10 Oct 2024
At a glance
- Drugs SGX 001 (Primary)
- Indications Chronic granulomatous disease
- Focus Adverse reactions
- 10 Oct 2024 New trial record
- 08 Oct 2024 According to Somagenetix AG media release, company looks forward to starting clinical application of SGX-001 during 2026.
- 08 Oct 2024 According to Somagenetix AG media release, company announced today the initial closing of its Series A financing round, raising CHF 10 million and the funds will enable Somagenetix to advance its leading gene therapy-candidate, SGX-001, into a clinical trial for the treatment of p47 Chronic Granulomatous Disease (CGD).